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Abstract: Infections with Hepatitis viruses B and C pose major problems both short and long 
term  respectively  after  HSCT.  The  key  to  prevention  for  Hepatitis  B  disease  remains 
vaccination for HBV-naïve patients and judicial use of anti
post-transplant  settings  for  HBV
recipients result in transmission of the virus in about 50%. The newer anti
enabled effective treatment of post
might  develop  so.  Selecting  a  previously  infected  donor  who  has  high  titres  of  surface 
antibody for HBsAg positive patients gives the best chance for immunological clearance. The 
most challenging aspect of preventing HBV reactivation remains the duration of anti
therapy and timing of its withdrawal as most reactivations and often fatal ones occur after 
this  period.  Hepatitis  C, on  the other  hand  affects  long
fibrosis  and  cirrhosis.  Early  effect  of  Hepatitis  C  virus  on  the  immune  system  remains 
conjectural. The standard combination therapy seems to be effective, but data on this front 
remains sparse, as in the case of the use of newer antiviral agents. HSCT from HCV infe
grafts  result  in  more  consistent  transmission  of  the  virus  and  pre
donors  should  be  undertaken  to  render  them  non
understanding  and  recommendations  regarding  prevention  and  management  of  these 
infections in HSCT recipients are discussed.
Introduction:  Haematopoietic  Stem  Cell 
Transplantation (HSCT) has evolved over the last 
three decades from a procedure limited to high
haematological  malignancies  with  high  risk  of 
morbidity  and  mortality  to  a  much  more  widely 
applicable one across age and donor ba
the  explosive  expansion  of  indications  for  HSCT 
and  the  new  and  novel  techniques  of 
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Infections with Hepatitis viruses B and C pose major problems both short and long 
term  respectively  after  HSCT.  The  key  to  prevention  for  Hepatitis  B  disease  remains 
naïve patients and judicial use of anti-viral therapy in both pre
transplant  settings  for  HBV-infected  patients.  HBsAg  positive  grafts  to  HBV
recipients result in transmission of the virus in about 50%. The newer anti
enabled effective treatment of post-transplant patients who might be lamivudine
might  develop  so.  Selecting  a  previously  infected  donor  who  has  high  titres  of  surface 
antibody for HBsAg positive patients gives the best chance for immunological clearance. The 
preventing HBV reactivation remains the duration of anti
therapy and timing of its withdrawal as most reactivations and often fatal ones occur after 
this  period.  Hepatitis  C, on  the other  hand  affects  long-term survival  with  early onset of 
nd  cirrhosis.  Early  effect  of  Hepatitis  C  virus  on  the  immune  system  remains 
conjectural. The standard combination therapy seems to be effective, but data on this front 
remains sparse, as in the case of the use of newer antiviral agents. HSCT from HCV infe
grafts  result  in  more  consistent  transmission  of  the  virus  and  pre-donation  treatment  of 
donors  should  be  undertaken  to  render  them  non-viremic,  if  possible.    The  current 
understanding  and  recommendations  regarding  prevention  and  management  of  these 
nfections in HSCT recipients are discussed.
Haematopoietic  Stem  Cell 
Transplantation (HSCT) has evolved over the last 
three decades from a procedure limited to high-risk 
haematological  malignancies  with  high  risk  of 
morbidity  and  mortality  to  a  much  more  widely 
applicable one across age and donor barriers. Given 
the  explosive  expansion  of  indications  for  HSCT 
and  the  new  and  novel  techniques  of 
transplantation,  the  nature  of  complications, 
particularly  the  opportunistic  infections  have 
evolved as well.  Hepatitis B and C virus infections 
are  widely  prevalent  amongst  the  general 
population, though differentially across the various 
continents.  The  impact  of  these  infections  on 
transplant outcome is getting better recognised. A 
recent guideline published jointly by the CIBMTR, 
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Table 1. Evidence-based rating system used in this article.
Strength of Recommendation
Category Definition
A Both strong evidence for efficacy and substantial clinical benefit support
recommendation for use. Should always be offered
B Moderate evidence for efficacy—or strong evidence for efficacy, but only limited clinical benefit—
supports recommendation for use.  Should generally be offered.
C Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for 
efficacy might not outweigh adverse consequences, (e.g., drug toxicity, drug interactions), or cost of 
the chemoprophylaxis or alternative approaches. Optional.
D
Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against 
use. Should generally not be offered.
E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. 
Should never be offered.
Quality of Evidence supporting the recommendation
Category Definition
I Evidence from at least one well-executed randomized, controlled trial 
II Evidence from at least one well-designed clinical trial without randomization; cohort or case-
controlled analytic studies (preferably from more than one center); multiple time-series studies; or 
dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or 
reports of expert committees
CDSC and other organisations have tried to address 
these  issues  from  a  global  perspective
1.  In  this 
article  we  shall  discuss  the  issues  related  to  the 
prevention and treatment of Hepatitis B and C in
patients  receiving  HSCT.  The  recommendations 
made are categorised as per the level of evidence 
(Table 1).
HEPATITIS B
Epidemiology: Over 350 million people are HBV 
carriers  worldwide,  with  the  infection  being 
endemic  in  several  countries.    The  prevalence  of 
chronic  hepatitis  B  infection  in  endemic  areas  
range from 5-25%,  whereas, that in non-endemic 
regions  are  less  than  0.5%
2,3.  The  prevalence  of 
HBsAg  positivity in patients with haematological 
malignancies  in  the  USA  and  western  Europe  is 
between is between 1-3.5%. In endemic populations 
in  Asia,  the  frequency  of  the  same  goes  up  to 
10%
4,2,3.
Natural  history  of  hepatitis  B  infection:  The 
course and outcome of HBV infection depends on 
two  factors:  age  at  infection  and  the  host-virus 
interaction.    Neonatal  infection  usually  results  in 
persistent infection, but acquisition of the virus later 
in  life  most  commonly    result  in  acute  hepatitis. 
Whilst acute viral hepatitis is self-limiting, a small 
minority (<5%) can progress  to fulminant hepatic 
failure. About 10% of those infected after the first 
two years of life would be a chronic carrier, with 
20% of those developing cirrhosis. Again, 25% of 
those  with  hepatitis  B  associated  cirrhosis  could 
develop hepatocellular carcinoma
5(Table 2).
Risk  factors  for  HBV  reactivation  post-
transplant  and  long  term  outcome:  HBV 
reactivation  post-transplant  is  characterised  by 
rising  levels  of  HBV  DNA  in  blood  during  the 
period of severe immunosuppression preceeding the 
rise in liver enzymes (ALT and AST) at the onset of 
immune  recovery.  Unless  serially  monitored,  this 
sequence of events might be missed, as the HBV 
load might not be as high at the onset of clinical 
hepatitis  which  marks  the  recovery  of  cellular 
immunity.  Although  any  chemotherapeutic    or 
immunosuppressive agent used during conditioning 
increases  the  risk  of  HBV  reactivation,  steroids 
pose the greatest risk.  Steroids facilitate replication 
of HBV through a glucocortcoid responsive element 
in  the  viral  DNA
6,7.    Other  immunosuppressive 
agents  such  as  rituximab
8 and  alemtuzumab
9,6,7, 
which are used as a part of conditioning regimen 
with  increased frequency are  also associated with 
increased  risk  of  HBV  reactivation.  Reduced 
Intensity conditioning is associated with similar or 
higher incidence of viral reactivations depending on 
the use of in-vivo anti-T cell antibodies. There is 
limited  data  on  Hepatitis  B  reactivation  in  this 
setting  and  deaths  have  been  reported  following 
cessation of anti-viral therapy. The greatest risk of 
HBV  hepatitis  is  at  the  time  of  withdrawal  of 
immunosuppression and very close monitoring is Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Table 2. Definitions for hepatitis B infected states.
Chronic asymptomatic HBsAg carrier HBsAg positive beyond 6 months with normal levels of liver enzymes (ALT and AST). 
Low level viral replication in serum.
Chronic symptomatic hepatitis B As above with 3- fold raised liver enzymes (ALT and AST) on two separate occasions.
Occult HBV carrier HBsAg negative, anti-HBc positive, anti-HBs positive or negative, low level viral 
replication in serum, normal liver enzymes.
Resolved HBV History of proven hepatitis B infection with negative HBsAG and HBV DNA, normal 
liver enzymes, but positive anti-HBc  and anti-HBs (may be negative)
HBV reactivation symptomatic or asymptomatic rise in HBV DNA followed by rise in liver enzymes 
(ALT and AST) in a known HBsAg carrier.
Reverse sero-conversion progressive loss of anti-HBs antibodies along with rising viral load and reappearance of 
HBsAg
warranted at that point.  Preemptive therapy should 
cover and extend well beyond this period to negate 
this effect. Markers of humoral  immunity are  not 
reliable indicators of virus specific immunity in the 
post-transplant  period,  particularly  in  those 
receiving IVIG. Hence, it is recommended that the 
HBV status be monitored by the viral load. HBeAg 
and anti-HBe which are often monitored in patients 
with chronic hepatitis should not be considered as 
only  indicators  of  viral  replication  either  pre- or 
post-HSCT.  Sensitive and quantitative PCR assays 
should be employed in diagnosing  and monitoring 
HBV  infection  pre  and  post-HSCT.  Moreover, 
patients who have apparently recovered from HBV 
infection  based  on  serological  markers,  can  still 
harbour the virus in the hepatocytes
10.  Subsequent 
to  the  loss  of  protective  anti-HBs  titres  and 
compromised cellular immunity, these patients can
reactivate  HBV  from this  site.  Hence, in  patients 
with previous infection with HBV, even if the pre-
transplant parameters  indicated resolved infection, 
HBV reactivation can still occur from latent sites 
such  as  hepatocytes  on  the  loss  of  protective 
immunity.  This  is  referred  to  as  reverse 
seroconversion.  In  the  context  of  autologous 
transplants, this risk was deemed to be greatest in 
patients  transplanted  for  myeloma
48,  while  in 
allogeneic  transplantation  those  on  high  dose 
steroids and with chronic GVHD are possibly at a 
greater  risk.  Precore  mutatants  (1896 G-A)  are 
associated with a higher risk of HBV reactivation 
and  severe  hepatitis
48.    A  serological  profile  of
positive HBsAg, positive HBV DNA, positive anti-
HBe  and  negative  HBeAg  should  suggest  the 
presence  of  pre-core  mutataion.  This  can  be 
confirmed by PCR assay for the mutation or direct 
sequencing. Early or unexplained breakthrough on 
lamivudine therapy should also raise suspicion of 
this  mutant form. In addition,  superinfection  with 
other  hepatotrophic  viruses    might  result  in 
precipitation or worsening of hepatitis in a HBsAg 
positive  recipient
12.  Drugs  and  GVHD  could  also 
complicate the picture. A liver biopsy is warranted 
in  all  such  situations  to  resolve  the  issue, 
particularly  if  GVHD  is  considered.  Hepatitis  is 
often a late feature post-allogeneic transplantation 
with a cumulative incidence of 20% at 5 years for 
HBsAg  positive  recipients  and  1%  in  anti-HBs 
positive recipients
13. This is noted much earlier in 
autologous  setting.  The  risk  of  HBV  hepatitis  in 
autologous  transplantation  is  similar  to  that 
following  an  allograft
14.    The  risk  of  hepatitis  is 
reduced only in those achieving sustained clearance 
of  HBV  through  adoptive  transfer  of  natural 
immunity  from  the  donor
13.  Unlike  HCV,  the 
incidence  of  cirrhosis  or  HCC  is  not  increased 
following  allogeneic  HSCT  in  HBsAg  positive 
donors when compared to the normal population
13. 
HSCT Recipient: Every HSCT recipient should be 
screened  for  evidence of  past  or  current  HBV 
infection.  The  screening  should  comprise  of  anti-
HBc, HBsAg and anti-HBs (AII).  This  should be 
carried out in every patient much before HSCT, ie 
before initiation of chemotherapy for malignancy or 
transfusion  for  non-malignant  disorders  or  at  the 
earliest stages of consideration for HSCT. 
No past exposure to HBV infection: If the above 
parameters  are  negative,  the  patient  should  be 
immunised with two doses of hepatitis B vaccine at 
3-4 weeks interval  before initiating chemotherapy 
or  transfusion  and  preferably  the  third  dose  at  6 
months (AII). This is often not possible in patients 
undergoing  chemotherapy  for  newly  diagnosed 
cancers. The third dose in these patients should be 
administered  a  few  months  after  completion  of 
chemotherapy.  The  chances  of  response  to 
immunisation are over 90% in normal individuals, 
but  this  is  much  lower  in  patients  undergoing 
chemotherapy (less than 60%). 
Past  exposure  to  HBV  infection  (AIII):  Past 
exposure to HBV in a HSCT recipient increases the 
risk of HBV reactivation post-transplant depending 
on  the  sero-status.  The  possible  scenarios  are
described  in  Table  3.  A  negative  HBsAg  withMedit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Table 3. Investigations based on HBV sero-status of the recipient.
HSCT RECIPIENT SERO-STATUS INVESTIGATIONS
HBsAg negative
antiHBc positive 
anti-HBs positive
1. Repeat the profile
2. If anti-HBs positive: proceed with HSCT 
3. If anti-HBs negative: check for HBV DNA 
a. If negative, complete vaccination schedule 
b. If HBV DNA positive: quantitate viral load and 
proceed with preemptive therapy (see text)
HBsAg negative
antiHBc positive
anti-HBs negative
Check HBV DNA
1. If HBV DNA negative, complete vaccination 
schedule
2. If HBV DNA positive, proceed as below.
HBsAg positive 1. Check viral load
2. Proceed with pre-emptive therapy (see text)
evidence  of  antibodies  to  HBc  indicates  past 
infection  and  does  not  rule  out  the  possibility  of 
reactivation  during  post-transplant 
immunosuppression,  unless  anti-HBs  titres  are 
protective (> 10 IU/l). Hence all such patients with 
absent or low titres of anti-HBs, should be checked 
for HBV-DNA. If HBV-DNA is negative, attempt 
should be made to boost the HBV-immunity with 
vaccination. Those  who  fail  to  achieve  protective 
titres  should  be  monitored  closely  as  they  are  at 
high  risk  of  reactivation.  All  HBsAg  positive  or 
HBV DNA positive patients with evidence of recent 
hepatocellular injury should undergo a liver biopsy 
prior to  HSCT, because pre-existent  cirrhosis and 
hepatic  fibrosis  can  increase  transplant-related 
morbidity  and  mortality  (BIII).  It  is  not 
recommended routinely outside this setting.
HSCT Donor: Donors should be routinely screened 
using  same  parameters  as  the  recipient.    The 
possible scenarios with donor-recipient sero-status 
are  detailed  in  Table  4.  This  is  not  an  absolute 
contraindication  for  selecting  a  HBsAg positive 
donor  for  a  non-exposed  or  HBV-naïve  recipient 
(BIII). The overriding concern must be the HLA-
matching and other outcome-related concerns. The 
risk of transmission to HBV-naïve recipient is not 
100% and the exact risk remains unclear, although 
this can be estimated to be around 50%, based on 
the current evidence (AII)
15. Every attempt should 
be made if possible to immunise the recipient and 
render the donor non-viremic and the graft in-turn 
HBV-DNA  negative.  Those  who  mount  a  good 
antibody  response  post-vaccination  and  receive  a 
HBV-negative  graft  following  treatment  of  the 
donor  are  at  no  greater  risk  of  HBV  reactivation 
than those receiving grafts from HBV-naïve donors. 
However,  in  most  situations,  HSCT  could  be 
deemed necessary at the earliest and vaccinating the 
recipient or treating the donor to non-viremic stage 
might not be feasible. The best option then lies in 
reducing the volume of the graft (ie reducing the 
viral load) and passive immunisation of the HSCT 
recipient  immediate  pre-transplant.  Such  patients 
should be treated in the same way as HBV infected 
patients with close monitoring of viral DNA load, 
liver  enzymes  and  preemptive  antiviral  therapy. 
HSCT  from  HBsAg  negative,  anti-HBc  positive 
donors depend on their anti-HBs titres and presence 
or  absence  of  viremia  (Table  5).  However  those
previously  infected  donors    who  have  protective
anti-HBs  titres  should  be  preferred  for  a  HBV
infected  patient  as  this  offers  the  possibility  of
Table 4. Investigatons for the donor based on donor and recipient sero-status.
DONOR STATUS RECIPIENT STATUS RECOMMENDATIONS
HBsAg negative 
anti-HBc positive 
anti-HBs negative 
HBV-naïve  Check for HBV DNA
1. If negative, check at the time of harvest
2. Proceed without intervention, if negative
3. Treat as Table 5 if positive
HBsAg negative
anti-HBc positive
anti-HBs positive
HBV-naïve  Confirm profile
1. If antiHBs positive, proceed without intervention. 
2. If antiHBs negative, check HBV DNA and proceed 
accordingly.
HBsAg negative
anti-HBc positive
anti-HBs positive
HBsAg positive  Confirm profile
Preferred donor compared to a HBV naïve donor (see text)Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Table 5. Recommendations for transplant from HBsAg positive donor to HBV naïve recipient.
a. Measure HBV DNA in the patient.
b. Exclude precore mutant form
c. Treat donor with lamivudine for at least 4 weeks or until HBV DNA is undetectable (if time permits)
d. Active immunisation of the patient with at least two doses at 4 weeks interval (poor response anticipated in severely pre-
treated patients).
e. Reduce harvest volume to minimum without compromising planned CD34positive cell dose. Test harvest product for HBV 
DNA
f. If antiHBs titre is less than 10 IU/l, passive immunization with HBV immunoglobulin immediate pre-infusion of stem cells.
g. If donor and harvest HBV-DNA negative and patient anti-HBs titre protective, consider monitoring with frequent HBV DNA 
and ant-HBs titre post-transplant and treat with lamivudine at the earliest sign of serconversion or detection of viral load.
h. If donor or harvest positive for HBV-DNA, treat pre-emptively with lamivudine as above.
i. Immunise recipient after immune recovery with 1-3 doses of HBV vaccine as needed, if remains uninfected (negative for 
HBsAg, anti-HBc, anti-HBs and HBV DNA).
j. In addition, all HBsAg positive or HBV DNA positive donors should be evaluated for chronic hepatitis/cirrhosis and HCC 
prior to stem cell donation.
immunological clearance of HBV following HSCT 
(see below).
Preventing  HBV  reactivation  post-transplant:
All patients who are positive for either HBsAg or 
HBV-DNA  and  those  who  receive  grafts  from 
similar  donors  are  at  the  highest  risk  of  HBV 
reactivation  (defined  as  ‘High  Risk’).  Those  who 
are  negative  for  HBsAg  or  HBV-DNA  pre-
transplant  but  have  low  anti-HBs  titres  or  those 
receiving grafts from HBsAg positive donors who 
are  rendered  non-viremic  following  antiviral 
therapy  are  deemed  to  be  at  risk  of  HBV-
reactivation albeit lower (defined as ‘Low Risk’). 
Such patients should be closely monitored for viral 
load and liver function (Table 6). 
There are two approaches to address this.
1. Intervening  on  diagnosis  of  hepatitis  B 
reactivation
2. Pre-emptive intervention pre-transplant.
The current evidence weighs heavily in favour 
of preemptive intervention (AI).  In patients who go 
to  autologous  HSCT  with  high  viral  load  (>  10
5
copies/ml)  are  at  the  greatest  risk  of  HBV 
reactivation
16. A  significant  body  of  evidence 
including a couple of randomised studies and recent 
systematic reviews and metanalysis on the role of 
preemptive  intervention  in  patients  undergoing 
chemotherapy for malignancies strongly support the 
use  of  a  pre-emptive  approach
17,18,14,19,20,21.  This 
approach not only reduced the incidence of HBV 
reactivation  and  hepatitis,  both  severe  and  non-
severe, but also significantly reduced both overall 
mortality  and  hepatitis  associated  mortality. 
Extrapolation of these evidences to HSCT, coupled 
with  several  large  case-series  would  justify  pre-
emptive approach in these categories. 
Pre-emptive Intervention: Anti-viral agents which 
inhibit DNA polymerase are extremely effective in 
rapidly suppressing viral replication. All the studies 
referred to  above have employed lamivudine at  a 
dose  of  100  mg/day.  Although  lamivudine  is 
relatively  non-toxic,  prolonged  use  leads  to 
selection of YMDD mutant strains
2. Such mutants 
are generally responsive to adefovir dipivoxil
23,24 or 
entecavir
25.  In  trials  on  patients  with  chronic 
hepatitis, only 3.2% of lamivudine-resistant patients 
developed  resistance  to  adefovir  at  12  months. 
Moreover,  a  combination  of  adefovir  and 
lamivudine  led  to  quicker  response  and  less 
resistance than adefovir used alone
26. Newer drugs 
such  as  entecavir  and  tenofovir  are  more  potent 
anti-virals  and  the  latter  is  effective  against  both 
lamivudine  and  adefovir-resistant  strains
27. 
However, there is no study to support their usage as 
first-line  therapy  in  post-transplant  patients,  but 
might be considered in situations where prolonged 
anti-viral therapy is warranted.
Duration of therapy: There is no clear guideline 
on the optimum duration of treatment.  In patients 
receiving chemotherapy, discontinuation of therapy 
very soon after completion of chemotherapy leads 
to HBV reactivation and hepatitis similar to those 
not  receiving  treatment.  Hence,  it  is  justified  to 
continue antiviral therapy for at least 6 months post-
transplant in autologous transplants and 12 months 
post-transplant in allogeneic transplants, or longer if 
patient  is  on  immunosuppression  for  chronic 
GVHD (BIII). Extended use of lamivudine, not only 
results  in  reduction  of  HBV  reactivation  and  the 
resultant  complications,  but  also  impacts  HBV-
associated mortality
28,29. Monitoring of HBV-DNA 
levels and liver enzymes for at-least three months is 
advisable  after  stoppage  of  anti-viral  therapy  as 
there  is  a  risk  of  rebound  viral  replication  and 
immune-mediated  liver  injury after  withdrawal  of 
both anti-viral and immunosuppressive drugs.
Adoptive  transfer  of  immunity  to  HBV: 
Immunity  to  HBV  can  be  adoptively  transferred 
from the donor to the recipient.  Anti-HBs positive 
marrow donation has resulted in durable anti-HBs Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Table 6. Suggested management for patients at risk of HBV reactivation post-transplant.
Investigations Liver function test: 
 weekly for first 6 months
 then fortnightly until stoppage of all immunosuppressive and anti-viral therapy
HBV-DNA: 
 quantitative assay fortnightly if patient is not on anti-viral therapy 
 monthly if on anti-viral therapy.
 Immediately if there is threefold rise in liver enzymes 
 Fortnightly for three months after cessation of antiviral therapy
 If there is evidence of reverse sero-conversion at any stage
Management Low risk: 
 Monitoring and anti-viral therapy on earliest sign of HBV reactivation or                       reverse 
seroconversion.
High-risk
 Prohylaxis with  antiviral  drugs  until  three  months  after  cessation  of  all  immunosuppressive 
medications, if there is no evidence of rising viral load.
 Change to second line antiviral therapy if there is a rise in viral load on first line therapy
expression in the recipient
30. This has also resulted 
from  DLI  from  vaccinated  donors
31.  More 
importantly, transplants from HBV immune donors  
to  HBsAg  positive  patients  have  resulted  in 
sustained clearance of HBV infection. This is more 
likely  to  happen  after  natural  infection  than  after 
active  immunisation
32.  In  the  largest  follow-up 
study  reported  to  date,  65%  of  HBsAg  positive  
recipients  had  sustained  clearance  of  HBsAg  , 
following transplantation from donors with natural 
immunity to HBV. This process was augmented by 
preemptive lamivudine therapy
13.
Reverse Seroconversion post-transplant: Patients 
who  are  anti-HBs  and  anti-HBc  positive  pre-
transplant are considered to be at negligible risk of 
HBV  reactivation.  However,  over  50  cases  of 
reverse  seroconversion  have  been  reported  in  the 
literature, following both autologous and allogeneic 
transplantation, with an approximate overall risk of 
1%
33,13,34. This  probably results from undetectable 
levels  of  virus  in  serum  or  virus  residing  in 
hepatocytes  with  serum  negative  for  HBV  DNA. 
This  phenomenon  is  characterised  by  progressive 
loss of anti-HBs antibodies along with rising viral 
load and reappearance of HBsAg.  This can result in 
asymptomatic carrier state, symptomatic hepatitis or 
rarely fulminant hepatic failure. Anti-HBs positive 
patients  should  have  anti-HBs  monitored  every  3 
months and sudden or progressive reduction in anti-
HBs titre should prompt HBV DNA test
35. Patients 
on  high  dose  steroid  therapy  or  on 
immunosuppression  for  chronic  GVHD  ,  who 
receive  the  graft from  a  HBV-naïve  donor  are  at 
particular  risk  of  reverse  seroconversion.  Those
loosing  anti-HBs  response  should  receive  active 
immunisation  in  an  attempt  to  restore  protective 
levels of anti-HBs, if there is no evidence of HBV 
DNA in serum (BIII).
Transfusion-Risk: In UK for example, the risk of 
acquiring  hepatitis  B  through  transfusion  is  I  in 
150,000. The same is not true for many Asian or 
Latin  American  countries,  where  the  disease  is 
endemic  and  prevalent  in  upto  25%  of  the 
population  in  certain  areas.  The  importance  of 
active  immunisation  in  unexposed  patients  before 
administration  of  blood  products  cannot  be 
overemphasised (AII). However, this is not always 
practicable and a proportion of patients would be 
poor-responders.  All  patients  should  have  the 
serological profile repeated prior to HSCT, even if 
they  were  HBV-naïve  and  immunised  prior  to 
chemotherapy.  This is because of the possibility of 
reverse  seroconversion  through  the  period  of 
cytotoxic  and  immunosuppressive  therapy  which 
most would be exposed to prior to transplantation 
(AIII).
Sexual  Transmission:  Anti-HBs  negative  HSCT 
recipients  who  have  recived  a  graft  from  HBV-
naïve donor and have not been immunised or have 
failed  to  mount  a  response  to  vaccination  are  at 
increased risk of acquiring HBV from an infected 
partner.  Those  who  experience  loss  of  anti-HBs 
post-transplant are also at similar risk. Late hepatitis 
from sexual transmission has been reported
36 Both 
groups  should  be  advised  adequate  sexual 
protection and early vaccination if the partners are 
known HBsAg carriers (AIII).
HEPATITIS C
Epidemiology: Globally, about 170 million people 
are  chronically  infected  with  Hepatitis  C  virus 
(HCV)  and  about  3-4  million  more  are  infected 
each year. The major mode of transmission is via 
infected blood products and infected needles shared 
by  drug-users  or  percutaneous  procedures.  The Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
prevalence of chronic HCV infection is  higher in 
Africa and South East Asia than in Western Europe 
and North America. However, the disparity is not as 
pronounced  as  in  HBV,  largely  because  of  the 
millions  infected  in  these  places  through  blood 
transfusion  before  1992,  when  second  generation 
anti-HCV testing came into being (WHO factsheet). 
Unsafe  blood products still  contribute  to  majority 
on  newly  acquired  HCV  in  countries  with  high 
prevalence of the infection.  
Natural course and relevance to HSCT: Majority 
of  patients  infected  with  hepatitis  C  do  not  have 
acute  clinical  manifestations,  unlike  HBV. 
However,  80%  of  those  infected  develop  chronic 
infection and 20% of chronic HCV infected cohort 
develop cirrhosis of the liver after 20-30 years with 
1-5% developing HCC. Prior to the identification of 
hepatitis C in 1989 and effective screening in 1992 
onwards,  several  million  people  were  infected 
globally through blood transfusion. In a look-back 
study,  Seattle  identified that  32%  of  355  patients 
who received a transplant in 1987-88 were infected 
with HCV
37. Several studies since have assessed the 
short and long term consequences of HCV infection 
in  HSCT  recipients.  There  was  no  evidence  of 
adverse effect of HCV short-term apart from reports 
of Veno-occlusive Disease (VOD) in some studies. 
However, it was not until 2004, that the long-term 
adverse effect of HCV started becoming apparent. 
Earlier studies of 5-10 years follow-up, did not find 
any  effect  of  HCV  on  mortality  or  morbidity
38. 
However,  all  the  studies  reported  a  rise  in  liver 
enzymes in HCV positive patients on withdrawal of 
immunosuppression, but liver failure was extremely 
rare. Fifteen years follow-up on a cohort of 96 HCV 
infected  patients, revealed a  cumulative incidence 
of biopsy-proven cirrhosis of 11% and 24% at 15 
and  20  years  respectively
39.    The  risk  factors  for 
progression  to  cirrhosis  in  HCV  infected  HSCT 
recipients  were  extra-hepatic  manifestations  and 
genotype  C.    It  was  further  documented  in  this 
study that allogeneic HSCT  is the only risk factor 
for  early  progression  to  cirrhosis,  occurring  at  a 
median of 18 years compared to those not receiving 
HSCT. The seattle group also reported HCV as the 
major  cause  of  cirrhosis  following  allogeneic 
transplantation
40. A recent retrospective study on 31 
HCV infected patients showed an increase in non-
relapse  mortality  in  these  patients  compared  to 
matched controls. The causes of death were related 
not  to  liver  disease  per  se,  but  more  infectious 
complications.  Whether this is secondary to a direct 
or  indirect  effect  of  Hepatitis  C  virus  on  the 
recovering  immune  system,  remains  open  to 
speculation.  Similar to Hepatitis B, there is scant 
data on the outcome of Hepatitis C infected patients 
following reduced intensity transplantation.
Preventing HCV Infection
HSCT recipients: HCV infection in the recipient 
without  any  evidence  of  liver  damage  is  not  a 
contraindication  for  HSCT.    The  only  short  term 
risk is probably associated with VOD.  However, all 
HSCT recipients  should be assessed with careful 
history, examination and liver function test for the 
risk of HCV infection (BIII). Anti-HCV antibodies 
must be tested in all HSCT recipients (AII). Those 
with history of transfusion before 1992 (this may 
vary  according  to  the  country  of  origin),  IV  or 
inhaled drug abuse, tattoos and unexplained rise in 
liver enzymes, should undergo nucleic acid testing 
for HCV despite a negative anti-HCV (AII). Anti-
HCV response takes 6 months to be detected or may 
never  be  detectable  in  a  small  proportion  of 
individuals  or  during  or  immediately  after 
prolonged  and  heavy  chemotherapy  or 
immunosuppression
41. Thus, confirmation of HCV 
infection is dependent on detection of HCV-RNA. 
All patients with HCV infection must be assessed 
by  a  hepatologist  for  evidence  of  chronic  liver 
disease.  The  following  clinical  situations  should 
warrant a liver biopsy (AIII):
1. Associated iron overload.
2. History of excessive alcohol intake.
3. H/O hepatitis C for over 10-15 years.
4. Clinical evidence of chronic liver disease.
Patients  with  evidence  of  cirrhosis  or  hepatic 
fibrosis should not be considered for conventional 
conditioning (DIII).
Risk of VOD: Two studies have suggested that the 
risk  of  VOD  is  increased  in  patients  with  HCV 
infection  and  raised  ALT  pre-transplant,  whilst 
others have suggested to the contrary.  However, in 
patients with iron overload with HCV infection with 
raised  ALT,  VOD  prophylaxis  could  be 
recommended  routinely,  in  the  absence  of  any 
conclusive evidence to the contrary (BIII).
HSCT Donor: Donors who are HCV-RNA positive 
invariably  transmit  HCV  to  uninfected  recipient. 
Recipients  show  evidence  of  viremia  in the 
immediate  post-transplant  period
42.  As  mentioned 
above,  the  risks  of  short-term  morbidity  and 
mortality are extremely low. However, the effect on 
long-term survivors is significant. Donors who are 
anti-HCV  positive  but  HCV-RNA  negative,  are 
unlikely to infect the recipient
42. Thus, patients who 
desperately  need  a  HSCT  and  do  not  have  an Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
alternative donor, can proceed with HSCT with full 
understanding  of  the  long-term  side-effects.  The 
donor should be assessed for chronic liver disease 
and  other  extra-hepatic  manifestations  of  HCV, 
which might contraindicate a bone marrow or stem 
cell harvest (EIII). All donors should be screened 
for  ant-HCV  antibodies.  All  anti-HCV  positive 
donors  should be tested for  HCV-RNA. Those  at 
high-risk of HCV infection should also be tested for 
HCV-RNA even if anti-HCV antibody is negative 
(AII).
Preventing  Progression  of  HCV-Associated 
Chronic Liver Disease
Treating HSCT recipients: The standard treatment 
for chronic hepatitis C infection is a combination of 
interferon  and  ribavirin,  which  produces  80% 
sustained virological response in genotypes 2 and 3 
and  40-50%  in  genotype  1
43,44.  More  recently, 
peginterferon  1.5  µg/kg  once  a  week  along  with 
ribavirin  was  found  to  be  more  efficacious  than 
standard IFN 3mU thrice a week
45. Treatment for 
hepatitis  C  has  not been  considered  seriously  in 
HSCT recipients until recently, for several reasons.  
Firstly, the risk of early progression to cirrhosis was 
underestimated.  Secondly,  there  were  concerns 
regarding  safety  of  IFN  in  HSCT  recipients.  A 
study on 36 HCV positive HSCT recipients treated 
with  IFN  alone  or  IFN  plus  ribavirin,  reported  a 
response rate of 10% and 20% respectively
39. The 
major  side-effects  were  related  to  anemia  which 
was  responsive  to  erythropoietin  and 
thrombocytopenia,  which  necessitated  interruption 
of  treatment.  The  response  rate  was  much  lower 
than those observed in immunocompetent patients, 
but similar to HIV-coinfected population
46.
Based on the current evidences, the following 
can be recommended (BIII):
1) Treatment  for  chronic  HCV  should  be 
considered  in  all  HSCT  recipients  in 
collaboration  with  a  hepatologist.  The 
indications are listed in Table 7.
2) Treatment  should  be  initiated  with  full-dose 
peginterferon and ribavirin.
3) Dose  modifications  should be  made based  on 
tolerance and cytopenias
4) The  treatment  should  be  continued  for  24-48 
weeks depending on response.
5) Sustained  Virological  Response  (SVR)  is 
defined as negative HCV-RNA 24 weeks from 
completion of treatment
Limited  data  suggests  improved  outcome  in 
HSCT recipients infected with HCV who respond to 
combination therapy.
Table 7. Indications for treatment of HCV post-transplant.
1. In CR from the original disease
2. Two  years  post-transplant  without  evidence  of  chronic 
GVHD
3. Off immunosuppression for 6 months
4. Normal blood counts and serum creatinine
5. Should have a baseline liver biopsy
6. Be treated for iron overload if present, before initiating 
therapy
7. No problems related to excess alcohol consumption
Preventing  transmission  of HCV  from  HSCT 
donor: As  mentioned  above,  HCV-RNA  positive 
donors  universally  transmit  virus  to  the  recipient 
immediately  following stem cell  infusion.  Donors 
who are anti-HCV positive but HCV-RNA negative 
are unlikely to infect the recipient. Based on these 
premises,  it  might  be  logical  to  attempt  viral 
clearance in the donor prior to stem cell harvest, if 
feasible. There are few reports on success of this 
method
47. Both the donor and recipient should be 
counselled  on  individual  risks  and  the  donor  be 
treated with standard combination therapy (BIII).
Conclusion: Hepatitis viruses B and C are widely 
prevalent in the  general  population and affect the 
outcome  of  HSCT.  Prevention  is  the  key  to 
overcoming  problems  related  to  these  viruses. 
However, proper strategies adopted in transplanting 
infected patients or grafts from infected donors can 
minimise both short- and long-term complications 
and fatal outcomes.
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